Tender detail
Biologic medicine rebate agreements 2026 – Ranibizumab, Lot 31
Summary
Participating health insurance funds are seeking rebate agreements with pharmaceutical companies for the active ingredient ranibizumab, under lot 31 of an open-house procedure. The agreements use uniform terms, provide no exclusivity, and may run for up to 24 months from 1 January 2027, ending no later than 31 December 2028.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.